STAT+: Pharmalittle: We’re reading about Lilly’s obesity pill, pharma deals with Trump, and much more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our […]
Mazdutide versus placebo in Chinese adults with type 2 diabetes – Nature
Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature Yahoo Finance Phase 3 Trial Shows Mazdutide Improves Blood Sugar Control in Type 2 Diabetes Patients geneonline.com 来曲肽对比度拉糖肽治疗中国2型糖尿病 Bioengineer.org 马兹杜替德对比安慰剂治疗2型糖尿病 Bioengineer.org
How weight-loss jabs are changing the way we eat
Babybel, the “small, ready-to-eat industrial cheese wrapped in its signature red wax”, is an unexpected beneficiary of anti-obesity drugs, said Le Monde. Its French-owned producer Bel is investing €60 million to ramp up production of the cheese in response to a 6% growth in global sales, and a 12% increase in the US. Healthy snacks […]
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial – Eli Lilly
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Lilly’s obesity pill largely maintains weight lost on injectable […]
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly – CNBC
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly CNBC Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Yahoo Finance A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound. MarketWatch […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound – CNBC
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Major Weight Loss and Knee-Pain Relief Seen With New […]
Eli Lilly Scores Another Major Win: Time to Buy?
Can anyone stop Eli Lilly (NYSE: LLY)? The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, in addition to having the top approved product in this category, it also has pipeline candidates that outshine […]
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one…
Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, is likely a factor.
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial released Thursday …